Vernalis Plc - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Vernalis Plc Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Vernalis Plc. The Group's principal activity is to develop and commercialize pharmaceutical products for a range of medical disorders. It has expertise both in de- novo structure and fragment-based drug discovery and pre-clinical and clinical development. The Group has seven product candidates in clinical development (two of which are partnered), two programmes in pre-clinical (one with a partner) and other competitive research programmes. The Group operates in the United Kingdom, Rest of Europe, North America and Rest of the World. On 01-Jul-2008, the Group completed the sale of Apokyn and Vernalis Pharmaceuticals Inc.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report